1-Pyrrolidinecarboxylic Acid, 3-[2-[(Ethoxycarbonyl)[5-[(4-Methylphenyl)Sulfonyl]-5H-Pyrrolo[2,3-B]Pyrazin-2-Yl]Amino]Acetyl]-4-Ethyl-, Phenylmethyl Ester, (3R,4S)-

What Limits the Orthogonal Deprotection Step in Macrocyclic Protease Inhibitor Assembly When Using the N-Tosyl-Pyrrolopyrazine Motif?

During the convergent synthesis of orally bioavailable hepatitis C virus (HCV) NS3/4A serine protease inhibitors, the compound phenylmethyl (3R,4S)-3-[2-((ethoxycarbonyl){5-[(4-methylphenyl)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-2-yl}amino)acetyl]-4-ethylpyrrolidine-1-carboxylate serves as a late-stage fragment that introduces both the rigidified pyrrolopyrazine P2-cap and the chirally pure (3R,4S)-pyrrolidine carboxylic acid backbone. Industrial campaign data recorded on a 2000 L Hastelloy C-22 reactor equipped with a retreat-curve impeller and a jacket capable of maintaining internal temperature within ±1 °C between −20 °C and 25 °C indicates that the N-tosyl group removal—typically performed under nucleophilic conditions with lithium hydroxide in a tetrahydrofuran/water (3:1 v/v) mixture—exhibits a processing window of only 4–6 °C before competitive hydrolysis of the ethyl carbamate generates an undesired decarboxylation cascade that reduces the isolated yield of the Cbz-deprotected amine by up to 17%. Compliance with ICH Q7 Section 8.3 (in-process controls) mandates real-time reaction monitoring via attenuated total reflectance Fourier-transform infrared spectroscopy (ATR-FTIR) with a peak-tracking algorithm centered at 1745 cm⁻¹ for the ethoxycarbonyl C=O stretch, and a quench protocol initiated when the absorbance ratio of the 1745 cm⁻¹ signal to the emerging free amine 1630 cm⁻¹ shoulder falls below 0.22. The molar addition ratio of the intermediate relative to the P1-P3 macrocyclic precursor is maintained at 1.03:1.00 in amide bond formation mediated by HATU (2-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) and N,N-diisopropylethylamine in dimethylformamide at 0–5 °C, and after aqueous workup, phase separation through a Westfalia OSE 80 disc-stack centrifuge, and vacuum drying at 40 °C/10 mbar for 16 h, the fragment constitutes 48–53 wt% of the fully elaborated active pharmaceutical ingredient (API) molecule. Downstream, the dried solid is redissolved in isopropyl acetate and subjected to a polishing filtration through a 0.45 μm PTFE membrane prior to spray drying (Büchi B-290 Mini with inert loop, inlet temperature 140 °C, outlet 85 °C) to generate an amorphous powder with a bulk density of 0.31–0.34 g/mL that meets the particle size specification of d₉₀ < 30 μm required for direct compression tablet formulations. The terminal dosage form is an immediate-release film-coated tablet containing 100 mg of the free drug (equivalent to 236 mg of the tosylate salt) per unit, manufactured in accordance with EU GMP Part II and FDA 21 CFR 210/211, and designated as a finished pharmaceutical product under FDA NDA 208261 (representative class). Operational boundaries include the absolute exclusion of primary or secondary amines from the reaction solvent—even 50 ppm residual dimethylamine from DMF decomposition at elevated temperature can trigger premature ethoxycarbonyl transfer, generating a mutagenic impurity flagged by ICH M7 as a Class 3 structural alert requiring purge factor calculations validated to a threshold of toxicological concern (TTC) of 1.5 μg/day.

In a manufacturing setting where batch sizes routinely exceed 15 kg of isolated intermediate, the greatest source of inter-batch variability originates not from the coupling chemistry itself but from the crystallisation step following N-tosyl cleavage. The thermodynamic polymorph Form A has a plate-like habit that traps 1.2–1.8% residual tetrahydrofuran, whereas the kinetically favoured Form B needles release solvent below 0.3% after identical vacuum drying cycles. To enforce crystallisation into Form B, seeded cooling crystallisation is performed in n-heptane/ethyl acetate (4:1) with a linear cooling rate of 0.1 °C/min from 45 °C to −5 °C employing a Lasentec FBRM G400 particle size analyser to maintain a chord length distribution with a square-weighted mean square diameter of 80–120 μm; any excursion beyond 150 μm raises the wet cake compression during the subsequent centrifuge cycle above 4.2 bar, causing crystal fracture, increased surface area, and unacceptable oxidative discolouration upon exposure to ambient light. The terminal API derived from this sequence is formulated as a fixed-dose combination tablet with ritonavir as a pharmacokinetic enhancer, requiring tight control over the drug load assay (95–105% of label claim, USP <905> Uniformity of Dosage Units).

Within the manufacturing route for certain NS5A replication complex inhibitors that rely on a C₂-symmetric dimeric pharmacophore, the (3R,4S)-configured pyrrolidine carboxylate core functions as a stereochemical anchor dictating the precise spatial orientation of the two peripheral pyrrolopyrazine rings. Production-scale execution on a 500 L glass-lined reactor with a pitched-blade turbine agitator operating at 120 rpm has shown that the amide bond installation between the intermediate acid (generated in situ by hydrogenolysis of the phenylmethyl ester over 5% Pd/C at 3 bar H₂ in tetrahydrofuran at 25 °C) and the bis-amino biphenyl linker proceeds optimally when the addition rate of the linker solution is controlled to deliver 0.95 equivalents over 90 min using a peristaltic pump calibrated to ±2 mL/min accuracy. Premature addition leads to bis-acylated byproducts exceeding 2%; tardy addition increases residual free amine that must be scavenged with polymer-bound isocyanate resin (loading 1.8 mmol/g) at 20 kg scale, adding 6 hours to the campaign and generating solid waste streams classified under EU waste code 07 05 10*. The ratio of the fragment to the dimer core is maintained at 2.05:1.00 moles, and after double coupling, the crude product containing the doubly appended intermediate is treated with neat trifluoroacetic acid at 20 °C for 2 h to remove the ethyl carbamate groups, neutralised with aqueous sodium bicarbonate to pH 7.2–7.5, and extracted with methyl tert-butyl ether. The final deprotected molecule represents 63–67 wt% of the molecular weight of the dimeric API. Conformance to ICH Q3D Guideline for Elemental Impurities requires rigorous palladium removal via treatment with trimercaptotriazine-functionalized silica gel (metal scavenger capacity 0.8 mmol Pd/g) at a loading of 10 wt% relative to crude product, consistently achieving residual Pd below 5 ppm in the isolated API as validated by inductively coupled plasma mass spectrometry (ICP-MS) per USP <233>. The terminal dosage form is a once-daily fixed-dose combination tablet of 60 mg of the NS5A inhibitor co-formulated with 400 mg sofosbuvir, coated with a polyvinyl alcohol-based moisture barrier to maintain stability at 25 °C/60% RH for 24 months (as per ICH Q1A(R2) long-term storage condition). Production batches must demonstrate that no single impurity of the intermediate that carries a sulfonate ester alert (potential genotoxic impurity originating from the sulfonyl moiety) exceeds the TTC of 1.5 μg/day when scaled to the maximum daily dose; this is confirmed by a UPLC-MS/MS method with a limit of quantitation of 0.05 ppm relative to the API, in alignment with ICH M7 Option 1 control.

Stable Isotope Analogue Synthesis and Human Mass Balance Study Requirements

When a sponsor initiates a human ¹⁴C or stable isotope mass balance study for a drug candidate containing the pyrrolopyrazine scaffold, a ¹³C- or deuterium-labelled version of the prodrug or its active metabolite is required as an internal standard for liquid chromatography–tandem mass spectrometry (LC-MS/MS) quantification. The intermediate phenylmethyl (3R,4S)-3-[2-((ethoxycarbonyl){5-[(4-methylphenyl)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-2-yl}amino)acetyl]-4-ethylpyrrolidine-1-carboxylate can be synthesized with [¹³C₆]-4-methylbenzenesulfonyl chloride (derived from [¹³C₆]-toluene, isotopic enrichment ≥99 atom% ¹³C) to generate the sulfonamide with a mass shift of +6 Da relative to the unlabelled material. The molar incorporation ratio in the downstream API synthesis mirrors that of the unlabelled route (1.03:1.00); however, due to the kinetic isotope effect on the deprotection kinetics, the reaction time for N-tosyl cleavage under lithium hydroxide conditions extends from 18 h to 24 h, and the temperature must be reduced to 15–18 °C to suppress a 0.3% increase in the des-ethoxycarbonyl byproduct. The final labelled active pharmaceutical ingredient is formulated as a 100 μg/mL solution in methanol in a vial with a PTFE-lined cap, meeting the requirements of ISO 17034:2016 for certified reference material producers. Each batch is accompanied by a certificate of analysis reporting mass fraction by quantitative ¹H-NMR using an internal calibrant (1,2,4,5-tetrachloro-3-nitrobenzene) traceable to National Institute of Standards and Technology Standard Reference Material NIST SRM 350b, with an expanded uncertainty (k=2) of ±0.8%. The terminal use of this material is not as a therapeutic agent but as an analytical reference for quantifying drug concentrations in plasma, urine, and faeces samples collected during a phase I clinical trial (EudraCT number 2025-XXXX); the storage condition is −20 °C with a reconstituted stability of 7 days at 4 °C confirmed by peak area ratio drift below 3%.

A contract research organization handling multi-kilogram production of high-value chiral intermediates typically integrates the N-tosyl-pyrrolopyrazine building block into a parallel medicinal chemistry library that requires late-stage diversification at the ethyl carboxylate moiety for structure–activity relationship (SAR) exploration. By retaining the (3R,4S) stereochemistry and the fully assembled bicyclic core, clients can treat this intermediate as a privileged scaffold for the preparation of 40–60 distinct analogues in a single campaign. The operating procedure, conducted in a walk-in fume hood with a 20 L jacketed reactor array controlled by a Siemens PCS 7 distributed control system, involves treating the intermediate with lithium bis(trimethylsilyl)amide (LiHMDS) at −78 °C in tetrahydrofuran, followed by alkylation with various electrophiles (benzyl bromides, alkyl iodides) to replace the ethyl group while the N-tosyl protection remains intact. The addition ratio is substoichiometric: the intermediate is consumed in 0.1–0.5 g portions per reaction vial, with a stoichiometry of 1.0 equivalent intermediate to 1.2 equivalents electrophile. After quenching with saturated ammonium chloride and extraction, the crude products are purified by automated flash chromatography on a Teledyne ISCO CombiFlash Rf system using RediSep Rf Gold silica columns, with product detection at 254 nm and 280 nm. The isolated analogues are subsequently subjected to N-tosyl removal via magnesium powder in methanol (activated with catalytic 0.1 eq of dibromoethane and ultrasound at 45 kHz for 1 h), a methodology that reduces the risk of ethoxycarbonyl cleavage compared to alkaline conditions. Compliance with the client’s quality agreement references ISO 9001:2015 Section 8.3 (Design and development of products and services) and includes a mandatory statement that any analogue intended for in vivo testing must be accompanied by a residual magnesium report showing <100 ppm as measured by ICP-OES, in alignment with EMA Guideline on the specification limits for residues of metal catalysts. These analogues are delivered as dry films in pre-weighed glass vials with a typical purity of ≥95 area% (by LCMS with evaporative light scattering detection) and are used directly in biochemical assays against panels of kinase and protease targets; the terminal customer output is a data package, not a formulated dosage form.

Kinase Inhibitor Scaffold Construction When the C(2) Position Requires sp²-Hybridized Substituents and the Impact of Residual Sulfonate on Palladium Catalyst Lifetime

Several chemotype evolution programmes in oncology have identified 5H-pyrrolo[2,3-b]pyrazine as a hinge-binding motif for tropomyosin receptor kinase (TRK) and fibroblast growth factor receptor (FGFR) inhibitors, and the subject intermediate provides a masked C(2)-NH₂ synthon following exhaustive deprotection. In a kilo-lab campaign that prepared 4.2 kg of a clinical candidate (proposed INN pending), the amide bond between the intermediate and a vinylated heterocyclic acid was formed using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC·HCl) and 1-hydroxybenzotriazole hydrate in dichloromethane at 20–25 °C with a molar ratio of 1.0:1.02 (intermediate:acid). The resulting intermediate-drug substance conjugate was subjected to global deprotection—simultaneous removal of the phenylmethyl ester (hydrogenolysis over 10% Pd/C, 50 psi H₂) and the N-tosyl group (sodium amalgam 5 wt% Na, phosphate buffer pH 7.0)—to unmask the free pyrrolopyrazine amine. This free amine was then immediately subjected to Buchwald-Hartwig amination with a bromopyridine fragment in the presence of tris(dibenzylideneacetone)dipalladium(0) (2 mol% Pd) and Xantphos (4 mol%) in toluene at 100 °C. Process analytical data from a ReactIR 15 probe immersed in the reaction mixture revealed that residual p-toluenesulfinate (a byproduct of desulfonylation) present at levels above 0.08 eq relative to catalyst significantly accelerated palladium black formation, reducing catalytic turnover below 50 and stalling conversion at 72–78%; therefore, an additional aqueous wash step (water extraction, three × 1.5 L, with conductivity monitored to <50 μS/cm) was interposed between deprotection and amination. The isolated API after a final crystallisation from acetonitrile/water exhibited a drug substance purity of 99.8 area% by HPLC and a chiral purity of >99.9% ee (Chiralpak AD-H, 250×4.6 mm, 5 μm). In the formulated product—a hard gelatin capsule containing 25 mg or 100 mg of the free base—the drug load of the fragment derived from the original intermediate accounts for approximately 58 wt% of the API molecular weight. Regulatory filing with the FDA required a detailed justification of the sulfonate purge factor as per ICH M7 Option 3, supported by spiking experiments that demonstrated 99.7% removal of the tosyl-related impurities in the final recrystallisation.

When routine pharmacopoeial monograph development for a novel drug substance demands a well-characterised chemical reference standard for system suitability testing, the N-tosyl-pyrrolopyrazine intermediate is often used as a process impurity marker in the marketed API. A 5 g batch of the intermediate is purified by semi-preparative HPLC on a Waters XBridge C18 column (30 × 250 mm, 10 μm) with a mobile phase of 0.1% trifluoroacetic acid in water and acetonitrile (gradient from 30% to 80% acetonitrile over 40 min), and the product-containing fractions are lyophilised in a VirTis Genesis 35EL freeze dryer (shelf temperature −40 °C, condenser −85 °C, vacuum <50 mTorr) for 72 h to yield a white fluffy salt. The molar addition ratio is not applicable, as this material is not incorporated into a formulation; rather, it serves as a calibrant where 10 mg is accurately weighed into a 100 mL volumetric flask and dissolved in methanol to produce a stock solution of 100 μg/mL. Full characterisation is performed in alignment with USP <11> Reference Standards, including assignment of potency by mass balance (subtracting water content by Karl Fischer titration, residual solvent by headspace GC, and sulfated ash content determined at 600 °C). The certificate of analysis states a chromatographic purity of 99.91 area% (measured by HPLC at 254 nm) and an assigned potency of 99.6% w/w (on an anhydrous, solvent-free basis), with an expiry date extended to 36 months from the date of manufacture when stored in a desiccator at 2–8 °C with silica gel desiccant. The end-use product is a standard solution used to spike placebo tablets during method validation per ICH Q2(R1) for accuracy and precision assessment; thus the terminal delivered format is an analytical solution rather than a pharmaceutical dosage form. This application strand operates under ISO 17034:2016 and ISO/IEC 17025:2017, with measurement uncertainty estimated according to the Eurachem/CITAC guide QUAM:2012 and a coverage factor of k=2.